Corpus Intelligence IC Memo — UNIVERSITY OF NEW MEXICO HOSPITAL 2026-04-26 09:08 UTC
IC Memo — UNIVERSITY OF NEW MEXICO HOSPITAL
Investment Committee Memorandum | NM | 554 beds | Grade B | EBITDA uplift $96.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

UNIVERSITY OF NEW MEXICO HOSPITAL

CCN 320001 | nan, NM | 554 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

UNIVERSITY OF NEW MEXICO HOSPITAL is a 554-bed large academic medical center in nan, NM with $1.31B in net patient revenue and a -15.3% operating margin. The hospital serves a payer mix of 12.6% Medicare, 5.7% Medicaid, and 81.7% commercial.

Thesis: Undervalued. Our ML models identify $96.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -15.3% to -8.0% (+736bps).

Net Revenue HCRIS$1.31B
Current EBITDA COMPUTED$-200.1M
Operating Margin COMPUTED-15.3%
Occupancy HCRIS86.6%
Revenue / Bed COMPUTED$2.4M
Net-to-Gross HCRIS53.4%
Distress Probability ML41.9%

2. Market Context & Competitive Position

55
NM Hospitals
-2.7%
State Median Margin
798
Comparable Hospitals

NM has 55 Medicare-certified hospitals with a median operating margin of -2.7%. The target's margin of -15.3% places it below the state median. Among 798 size-comparable peers (277-1108 beds), the median margin is -4.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (277-1108), prioritizing same-state peers. 798 hospitals in the comp set.

HospitalStateBedsRevenueMargin
UNIVERSITY OF NEW MEXICO HOSPI (Target)NM554$1.31B-15.3%
ST. LUKES HOSPITALPA633$8.94B87.9%
STANFORD HEALTH CARECA657$6.76B3.7%
VANDERBILT UNIVERSITY MEDICAL TN1084$5.44B-15.9%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
UNIV OF MI HOSPITALS & HLTH CTMI951$4.62B-1.4%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
CEDARS-SINAI MEDICAL CENTERCA908$3.92B-5.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $96.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$27.4M+210bp18mo
Cost to Collect4.5%2.5%$26.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$25.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$15.9M+122bp9mo
Clean Claim Rate88.0%96.0%$836K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$27.4M
Cost to Collect
$26.1M
Denial Rate Reduction
$25.9M
A/R Days Reduction
$15.9M
Clean Claim Rate
$836K
Total EBITDA Uplift$96.2M
Current EBITDA$-200.1M
+ RCM Uplift+$96.2M
Pro Forma EBITDA$-103.9M
Current Margin-15.3%
Pro Forma Margin-8.0%
WC Released (1x)$50.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-307.9M$-358.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-307.9M$-494.0M0.00x-100.0%
Bull Case9.0x11.0x$-277.1M$-276.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-277.1M$-383.5M0.00x-100.0%
Bear Case11.0x10.0x$-338.7M$-739.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-338.7M$-923.1M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 798 hospitals with 277-1108 beds
  • Same-state prioritization (n=3)
  • Comp margins: P25=-14.4% / P50=-4.5% / P75=4.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.